Drug Profile
Zalifrelimab - Agenus
Alternative Names: AGEN-1884; RebmAb-600; UGN-301Latest Information Update: 12 Apr 2024
Price :
$50
*
At a glance
- Originator 4-Antibody; Ludwig Institute for Cancer Research
- Developer Agenus; Nelum; Recepta biopharma; UroGen Pharma
- Class Antineoplastics; Immunoglobulins; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cervical cancer; Haemangiosarcoma; Non-small cell lung cancer; Soft tissue sarcoma
- Phase I/II Pancreatic cancer; Solid tumours
- Phase I Bladder cancer
- No development reported Cancer
Most Recent Events
- 28 Mar 2024 Agenus and Betta Pharmaceuticals withdraws a phase-II trial prior to enrolment in Cervical cancer (Montherapy, Combination therapy, Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable, Metastatic disease) in China (IV) (NCT05033132)
- 02 Jun 2023 Efficacy and adverse events data from a phase II trial in soft tissue sarcoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 31 May 2023 Selexis has merged with KBI Biopharma to form KBI Biopharma